Endocrine Society Challenges EPA's Vision Of Necessary Chemical Testing

摘要

The Endocrine Society is challenging EPA's draft position on nonmonotonic dose response curves (NMDRCs) and chemicals that exhibit these phenomena, arguing that EPA's recent white paper does not reflect newer science and ignores endocrine-related expertise in the agency's view that its existing testing regime is sufficiently protective. EPA last month released a draft white paper containing what is anticipated to become the agency's position on NMDRCs and whether it is necessary to change regulatory testing practices for chemicals that exhibit these challenging phenomena. The document is now under review by a new committee of the National Academy of Sciences (NAS), which held its first meeting July 23. During public comments at the brief open session of the meeting, the Endocrine Society's Jason Wexler outlined the group's concerns with EPA's draft position. "The society and members are concerned that endocrinology is not sufficiently considered in the" EPA white paper, Wexler said. "We hope that the [NAS] review will provide" more balance.